Raymond James Maintains LumiraDx (LMDX) Outperform Recommendation
Fintel reports that on April 7, 2023,
Raymond James
maintained
coverage of LumiraDx (NASDAQ:LMDX) with
a Outperform recommendation.
Raymond James
maintained
coverage of LumiraDx (NASDAQ:LMDX) with
a Outperform recommendation.